Showing results (81-90 of 162) with videos related to

Sort By:
Pageof 17
Nano Letters|October 1, 2021
Vessel-Targeting Nanoclovers Enable Noninvasive Delivery of Magnetic Hyperthermia-Chemotherapy Combination for Brain Cancer TreatmentFuyao Liu, Haoan Wu, Bin Peng, et al.
The Journal of Clinical Investigation|August 14, 2024
TET3-overexpressing macrophages promote endometriosisHaining Lv, Beibei Liu, Yangyang Dai, et al.
Gynecologic Oncology Reports|September 5, 2020
Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532]Alessandro D Santin, Virginia Filiaci, Stefania Bellone, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 5, 2011
Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibodyChristine E Richter, Emiliano Cocco, Stefania Bellone, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 3, 2011
Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibodyMarta Bellone, Emiliano Cocco, Joyce Varughese, et al.
Gynecologic Oncology|July 15, 2026
Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinomaSarah Ottum, Namrata Sethi, Stefania Bellone, et al.
Clinical & Experimental Metastasis|September 6, 2013
Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxelDana M Roque, Natalia Buza, Michelle Glasgow, et al.
Molecular Human Reproduction|March 12, 2016
Granulosa cell and oocyte mitochondrial abnormalities in a mouse model of fragile X primary ovarian insufficiencyCarola Conca Dioguardi, Bahar Uslu, Monique Haynes, et al.
BJC Reports|November 8, 2024
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analysesDana M Roque, Eric R Siegel, Natalia Buza, et al.
Medical Oncology (Northwood, London, England)|April 12, 2017
Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivoGulden Menderes, Elena Bonazzoli, Stefania Bellone, et al.
Pageof 17